Who are Beta Bionics, Inc.'s major customers?

Beta Bionics, Inc. (BBNX) key customers include: DISTRIBUTOR-A, DISTRIBUTOR-B, DISTRIBUTOR-C, DISTRIBUTOR-D, DISTRIBUTOR-E and 9 more. View the full customer network at chainsifter.com/chain/BBNX.

What sector is Beta Bionics, Inc. in?

Beta Bionics, Inc. (BBNX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Beta Bionics, Inc. (BBNX) Supply Chain: 17 Verified Relationships

0Suppliers

14Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Beta Bionics, Inc. (BBNX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

18Total relationships

1Distinct source URLs

12High confidence

0.816Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Beta Bionics, Inc. Suppliers

No suppliers on recordBeta Bionics, Inc. has not yet been matched to upstream suppliers in our database, or is still being processed.

Beta Bionics, Inc. Customers

Ticker	Name	Confidence	Evidence
DISTRIBUTOR-A	DISTRIBUTOR-A	92%	Distributor A accounted for 10.4% of net sales and 14.7% of accounts receivable, net for the three months ended March 31, 2026
DISTRIBUTOR-B	DISTRIBUTOR-B	92%	Distributor B accounted for 10.9% of net sales and 13.3% of accounts receivable, net for the three months ended March 31, 2026
DISTRIBUTOR-C	DISTRIBUTOR-C	92%	Distributor C accounted for 14.4% of accounts receivable, net for the three months ended March 31, 2025
DISTRIBUTOR-D	DISTRIBUTOR-D	92%	Distributor D accounted for 11.8% of net sales and 11.6% of accounts receivable, net for the three months ended March 31, 2026
DISTRIBUTOR-E	DISTRIBUTOR-E	92%	Distributor E accounted for 12.0% of accounts receivable, net for the three months ended March 31, 2025
DISTRIBUTOR-F	DISTRIBUTOR-F	92%	Distributor F accounted for 16.9% of accounts receivable, net for the three months ended March 31, 2025
DISTRIBUTOR-G	DISTRIBUTOR-G	92%	Distributor G accounted for 17.8% of net sales and 12.5% of accounts receivable, net for the three months ended March 31, 2026
DISTRIBUTOR-H	DISTRIBUTOR-H	92%	Distributor H accounted for 17.3% of net sales and 19.9% of accounts receivable, net for the three months ended March 31, 2026
ABBOTT-DIABETES-CARE-INC	ABBOTT-DIABETES-CARE-INC	62%	ile application delivers real-time glucose readings, trends and graphs, with data securely stored in the cloud. To maximize the commercial value of the iLet opportunity, we have assembled a team acro…
ABT	Abbott Laboratories	62%	Reciprocal relationship from ABT graph: Reciprocal relationship from BBNX graph: ile application delivers real-time glucose readings, trends and graphs, with data securely stored in the cloud. To max…
CAPITAL-RESOURCES	CAPITAL-RESOURCES	62%	periods presented, primarily due to higher payroll-related costs, public company expenses, including audit, legal and insurance services, and increased operational overhead to support business growth…
QUARTERLY-REPORT-EMERGING-GROWTH-COMPANY	QUARTERLY-REPORT-EMERGING-GROWTH-COMPANY	62%	cted Volatility—E xpected volatility is derived from the average historical stock volatilities of several public companies within our industry that we consider to be comparable to our business over a…
XERIS-PHARMACEUTICALS-INC	XERIS-PHARMACEUTICALS-INC	62%	ile application delivers real-time glucose readings, trends and graphs, with data securely stored in the cloud. To maximize the commercial value of the iLet opportunity, we have assembled a team acro…
XERS	Xeris Biopharma Holdings, Inc.	62%	Reciprocal relationship from XERS graph: Reciprocal relationship from BBNX graph: Reciprocal relationship from XERS graph: Reciprocal relationship from BBNX graph: ile application delivers real-time …

Beta Bionics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
BBNX-DEBT	Debt stack $6.9M	90%	Market cache reports total debt of $6.9M.
BBNX-DEBT-8085	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.
BBNX-DEBT-8084	Warrants outstanding: 13000	90%	xbrl warrant detail from xbrl 2025-12-31.

Beta Bionics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Beta Bionics, Inc..

Beta Bionics, Inc. Ownership

Holder	Name	Confidence	Evidence
BBNX-OWNER-MORGAN-STANLEY	MORGAN STANLEY	90%	13F overlay lists MORGAN STANLEY as top holder; 132 tracked holders.

Beta Bionics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
XERS	Xeris Biopharma Holdings, Inc.	100.00	1	['customer']
ABT	Abbott Laboratories	100.00	1	['customer']
AORT	Artivion, Inc.	50.00	2
ALVO	Alvotech	50.00	2
CORT	Corcept Therapeutics Incorporated	50.00	2
PSNL	Personalis, Inc.	50.00	2
ORANY	ORANGE	50.00	2
ONCO	Onconetix, Inc.	50.00	2
HAE	Haemonetics Corporation	50.00	2
GCTK	GlucoTrack, Inc.	50.00	2
CODX	Co-Diagnostics, Inc.	50.00	2
GRFS	Grifols, S.A.	50.00	2
DXCM	DexCom, Inc.	50.00	2
FLGT	Fulgent Genetics, Inc.	50.00	2
GRAL	GRAIL, Inc.	50.00	2
GIKLY	Grifols, S.A.	50.00	2
ENTA	Enanta Pharmaceuticals, Inc.	50.00	2
EXAS	Exact Sciences Corp	50.00	2
GIFOF	Grifols, S.A.	50.00	2
CVRX	CVRx, Inc.	50.00	2

Beta Bionics, Inc. Supply Chain